Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsWritten by Nathan Reiff. Article Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Elon Musk's $1 Quadrillion AI IPO
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion over the next eight years. Companies often pursue niche approaches, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, several promising treatments have shown strong potential—and with that comes the possibility of significant sales. Two smaller biotech companies have seen notable share-price momentum thanks to their leading oncology medicines. Beyond their therapeutic potential, these drugs could help the firms move beyond penny-stock or otherwise unstable status and toward sustainable revenue. In both cases, meaningful challenges remain, making these typical biotech investments high-risk ventures that could also produce outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle San Francisco is the strangest city in America right now—you can hop into a self-driving car and be chauffeured by a robot, but out the window you see addicts slumped in doorways, open-air drug markets, the mentally ill screaming at the sky, and entire city blocks consumed by homeless encampments. It's ground-zero for the most disruptive technological forces of our age, and Erez lives in the Bay Area plugged into the capital, the connections, and the companies reshaping the world—the advancements in AI, blockchain, computing, and biosciences are unlike anything the world has seen before, and a tsunami of disruption is coming for everything all at once. During our most recent broadcast, we exposed what we're calling the most asymmetric opportunity of our careers: an overlooked financial company hiding a multi-billion-dollar blockchain asset Wall Street hasn't priced in—it's one of those rare situations Warren Buffett would describe as raining gold when all you have to do is step outside if you want to get rich. Watch the broadcast before the window closes now Iovance Biotherapeutics Inc. (NASDAQ: IOVA) bucked market trends in early March, surging nearly 37% in a week when the S&P 500 fell about 1%. That added to IOVA's year-to-date (YTD) gains, which have more than doubled the share price. Still, with a consensus price target of $8.88, Wall Street appears to expect further upside—about 71% from current levels. The biggest catalyst for Iovance has been Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi has been approved in the United States since 2024 and is building momentum in sales, with potential additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin, the company's IL-2 immunotherapy, management believes Amtagvi could exceed $1 billion in peak U.S. sales. Amtagvi's potential may extend beyond melanoma: the drug received Fast Track designation from the FDA for non-small cell lung cancer and is being explored for other indications. Part of Iovance's outperformance this year followed its Q4 2025 earnings report, issued in late February, in which the company posted narrower-than-expected losses per share and recorded $5 million in revenue. For the full year, revenue rose roughly 30% year over year. Iovance remains a small-cap (about $2 billion) name and is still often treated like a penny stock. Despite the rally, analysts are cautious: roughly half of its ~12 ratings are Hold or Sell. Risks remain high — beyond the usual caveats for smaller biotechs, Amtagvi's manufacturing process is a major vulnerability. The therapy is personalized, expensive, and complex to produce, which could limit profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) fell about 20% in March, but its year-to-date performance dwarfs Iovance's: IBRX shares are up nearly 300% in 2026 so far. Analysts have set a price target of $13.60, roughly 70% above the stock's current level even after the recent run-up. ImmunityBio's primary growth driver is Anktiva, a treatment for certain bladder cancers. In February, shares jumped after the European regulator granted the drug conditional marketing authorization, the latest in a string of approvals around the world. Anktiva is driving the firm's revenue: the company reported $113 million in sales last year, about a 700% year-over-year increase. Like Amtagvi, Anktiva is also being explored for additional cancer indications, and ImmunityBio is actively pursuing other designations. Despite the massive surge over the last several quarters, IBRX remains speculative and risky. The company posted a full-year net loss of $351 million for 2025 as R&D spending continued to climb. Wall Street appears somewhat more positive than on Iovance, however: six of seven analysts rate the shares a Buy or equivalent. | 
